Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Address: Zolyomi ut 23 H-1118 Budapest,Hungary
Tel: +36 1 391 4455
Abiomics Europe Ltd.
„Advanced Biostatistics and Intelligence for the Omics”
Abiomics Europe Ltd. is a technology startup company that was founded in 2009 by bioinformatics and biomedical researchers along with investors. The cooperation between the Semmelweis University, Department of Genetics, Cell- and Immunobiology and the Budapest University of Technology and Economics, Department of Measurement and Information Systems started in 2005 and led to the establishment of the company.
The 5 years of cooperation and joint projects made it clear that modern life science research and development is not possible anymore without advanced information technology support. The GenaGrid consortium was founded in 2008 with the support of the National Office for Research and Technology when new academic and industry partners joined the research group and aims to develop various bioinformatics services. Abiomics Europe Ltd. is the company responsible for the utilization for the intellectual properties of the consortium and has all the exclusive rights for the developed technologies. Abiomics Europe drives the business development, market research and marketing activities for the consortium.
The GenaGrid research group and Abiomics Europe employs almost 30 informaticians and biomedical researchers. The group engages the technologies and software in Asthma and ALL research. The GenaGrid research group operates a genomics lab and the most powerful grid supercomputer dedicated for life science research in Hungary with 512 CPUs (March 2010).
Abiomics provides to their customers advanced information technology support.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be ignored by Roche. First of all, can…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies…
Assign Group started in 2002 as a small local CRO company founded in Austria; monitoring and doing minor project management only. Why was Austria chosen as the headquarters? First, it…
With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally planned economy and transformed into an open, pro-business economy…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other…
Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right…
Sanofi for 3,5 years. It must have been quite a different market, culture and environment. Yet, at that time you publicly announced that it only took you 30 seconds to…
See our Cookie Privacy Policy Here
